new molecules and indications for glp 1 medicines GLP-1R Signaling Functional in Incretin Therapy GLP1 medicines now address weight

After discontinuation, there was a pronounced rebound in weight (MD=4.13 kg, 95% CI: 1.60 to 6.65), BMI (MD=0.84 kg/m2, 95% CI: 0.37 to 1.32), WC (MD=3.64 cm, 95% CI: 2.27 to 5.01), and HbA1c (SMD=0.69, 95% CI: 0.50 to 0.89)

GLP-1 medications like semaglutide (Ozempic and Wegovy) are often around weight loss, but the science on long-term health changed my mind.

Not so much

Low energy and Ozempic face can be the downsides for people on GLP-1s, the increasingly popular drugs that go by the names Ozemic, Wegovy and Mounjaro.

Evidence-based comparison of CagriSema (amylin + GLP-1) and tirzepatide (GIP + GLP-1) for obesity, including REDEFINE and SURMOUNT trial data.